Objectives: A comorbid diagnosis of cancer and dementia (cancer-dementia) may have unique implications for patient cancer-related experience. The objectives were to estimate prevalence of cancer-dementia and related experiences of people with dementia, their carers and cancer clinicians including cancer screening, diagnosis, treatment and palliative care. Method: Databases were searched (CINAHL, Psychinfo, Medline, Embase, BNI) using key terms such as dementia, cancer and experience. Inclusion criteria were as follows: (a) English language, (b) published any time until early 2016, (c) diagnosis of cancer-dementia and (d) original articles that assessed prevalence and/or cancer-related experiences including screening, cancer treatment and survival. Due to variations in study design and outcomes, study data were synthesised narratively. Results: Forty-seven studies were included in the review with a mix of quantitative (n = 44) and qualitative (n = 3) methodologies. Thirty-four studies reported varied cancer-dementia prevalence rates (range 0.2%-45.6%); the others reported reduced likelihood of receiving: cancer screening, cancer staging information, cancer treatment with curative intent and pain management, compared to those with cancer only. The findings indicate poorer cancer-related clinical outcomes including late diagnosis and higher mortality rates in those with cancer-dementia despite greater health service use. Conclusions: There is a dearth of good-quality evidence investigating the cancer-dementia prevalence and its implications for successful cancer treatment. Findings suggest that dementia is associated with poorer cancer outcomes although the reasons for this are not yet clear. Further research is needed to better understand the impact of cancer-dementia and enable patients, carers and clinicians to make informed cancer-related decisions.
Introduction
An increase in the ageing population coupled with improved life expectancy, raises unique challenges for health and social care. It is estimated that by 2050, at least 30% of the global population will be aged 65 years or older resulting in the increased likelihood and management of chronic and multiple illnesses, otherwise known as multi-morbidity (Barnett et al., 2012; World Health Organization, 2015) . By 2040, it is predicted that nearly one quarter of people aged over 65 years in England and Wales will have a cancer diagnosis and older age is linked with poorer cancer outcomes including lower likelihood of successful completion of cancer treatment (Cancer Research UK, 2015; Maddams, Utley, & Møller, 2012) . An aging population is also linked to a projected increase in the world-wide prevalence of dementia as approximately 5%-9% (Prince et al., 2015) . Taken together, this means that the number of older people with comorbid cancer and dementia is also likely to rise; although it is currently unclear what the comorbid cancer-dementia prevalence is.
A diagnosis of dementia has additional implications in accessing healthcare for cancer diagnosis and treatment, due to cognitive functioning and communication difficulties associated with the disease (Dooley, Bailey, & McCabe, 2015) . Behaviour and psychological symptoms of dementia are also likely to also impact on undiagnosed acute illness and healthcare use (Hodgson, Gitlin, Winter, & Czekanski, 2011; Silwanowicz et al, 2016) . In the context of dementia, little is known about the experience of being diagnosed with cancer or the process of receiving cancer treatment, cancer-related decision-making and the impact of those decisions. The complexities of managing cancer in a person with dementia is likely to place a significant burden on patients, their family carers, and health care professionals (HCPs) including cancer clinicians, particularly with greater involvement in cancerrelated decisions placed to support the person with dementia (All-Party Parliamentary Group on Dementia, 2016; Alzheimer's Society, 2009; Guthrie Bruce, Alderson, McMurdo Marion, & Mercer Stewart, 2012) .
The aim of this review was to systematically identify and critically review studies that investigated the prevalence of comorbid cancer and dementia and its effect on cancer-related pathways including prevention, detection and diagnosis, cancer treatments and clinical outcomes including palliative care. Cancer patients', informal caregivers', and HCPs' experiences and views were included. Specific objectives were to:
(1) Estimate the prevalence of cancer-dementia (2) Describe cancer-related experiences of people with cancer-dementia, their informal caregivers and HCPs at any stage of the cancer pathway (3) Describe cancer-related outcomes for people with cancer-dementia
Methods

Search strategy and selection criteria
Given the likely range of mixed methods used to investigate cancer-dementia, this review was conducted using a structured narrative approach [13] and follows the PRISMA checklist for reporting systematic reviews (Moher, Liberati, Tetzlaff, & Altman, 2009; Pope, Mays, & Popay, 2007) . This approach enables qualitative and quantitative studies to be reviewed simultaneously in order to synthesise the existing evidence and identify gaps when it is not practical to apply metaanalytic review methods. A systematic search of electronic databases (CINAHL, BNI, Embase, PsycINFO and MEDLINE) was conducted in December 2015 and updated June 2016. All study designs were considered for inclusion with no publication date limitations. Two authors (LM and JY) reviewed papers for inclusion criteria and discussed any disagreements. The search strategy was tailored to the review objectives using combinations of the following MesH search terms, which were adapted for terms used by each database.
Comorbidity AND dementia OR Alzheimer OR lewy AND tumour OR cancer OR neoplasms AND prevalence AND economic OR Cost OR expenditure. Dementia OR Alzheimer adjacent by five words to cancer OR tumour OR neoplasm OR Oncol*, AND treatment outcome OR mortality OR experience OR burden OR distress OR attitude OR preference* adjacent by five words to patient OR carer OR clinician OR nurse OR doctor OR family OR relative AND/OR information adjacent by five words to needs AND/OR decision-making.
The reference lists of included studies and relevant review papers were scanned for additional studies not already found in the searches. An additional search of the main authors of included studies was conducted.
The following inclusion criteria were used:
(1) Participants aged 18 years and older (2) Investigated cancer-dementia using medical classification in methodology, e.g. International Classification of Diseases (ICD), medical notes or Diagnostic and Statistical Manual for Mental Disorders (DSM-V) psychiatric interview (3) Full empirical research article written in the English language
The following exclusion criteria were used:
(1) Comparisons between samples of patients with cancer and samples of patients with dementia (or other illness), but not those with cancer-dementia (2) Self-reported diagnoses (of cancer or dementia) not confirmed by a clinician (3) Reviews, opinions, editorials, conference abstracts, case studies Given the mixed methods of studies identified in the review, the Mixed Methods Appraisal Tool (MMAT; Pluye, Gagnon, Griffiths, & Johnson-Lafleur, 2009 tool was used to appraise each study that met inclusion criteria. This has been specifically developed for mixed-method reviews to appraise qualitative and quantitative designs concurrently. Each study receives an overall quality percentage score based on four items that reflect study design, appropriateness of outcome measures including validity, randomisation (if appropriate) and completeness of data. The score ranges from 0% to 100%; -(0% of quality criteria met); *(25% of quality criteria met); **(50% of quality criteria met); ***(75% of quality criteria met) or ****(100% of quality criteria met).
Results
In total, 47 studies met inclusion criteria and one or more of the review objectives (see Figure 1 ), 14 of which specifically investigated cancer-dementia as an aim of the paper. Most studies were conducted in the USA (n = 31), Denmark (n = 7), two studies each from the Netherlands, Sweden, and Japan, and one study from England, Taiwan and Switzerland (Table 1) . Three studies received a quality appraisal rating of -(0%), 13 studies received a rating of *, 14 received a rating of **, 17 studies met criteria for 3 of 4 items *** and one study met full criteria **** (100%). Studies are presented in the results using sub-headings related to each of the review objectives.
Objective 1
Prevalence of cancer-dementia
Thirty-four studies reported prevalence estimates using a range of settings predominantly nationwide, nursing homes and individual hospitals (see Table 2 ). All but three studies investigated the prevalence of dementia in samples of patients with cancer while one study reported cancer-related data in a nationwide sample of hospital in-patients with Alzheimer's disease (Beydoun et al., 2015) . The remaining two studies used a sample of end-of-life nursing home hospice residents including those with cancer-dementia (Miller, Gozalo, & Mor, 2001; Miller, Mor, Wu, Gozalo, & Lapane, 2002) .
The lowest prevalence rates for dementia were reported in five Danish studies of ovarian (0.2%), breast (both 0.5%) and prostate (both 0.6%) cancer (Nguyen-Nielsen et al., 2013; Ording et al., 2013 a; Ording et al., 2013 b; Ording et al., 2016; Tetsche, Nørgaard, Jacobsen, Wogelius, & Sørensen, 2008) . The highest cancer-dementia prevalence rates of 32% and 45.6% were reported in the two US studies with samples of nursing home hospice resident studies (Miller et al., 2001 (Miller et al., , 2002 . Seven studies compared dementia prevalence rates between cancer patients and a non-cancer control group; four studies reported similar rates between the two groups (range: 0.5%-1% in cancer-dementia and 0.4%-1.2% in non-cancer) (Erichsen, Horvath-Puho, Iversen, Lash, & Sorensen, 2013; Jorgensen, Hallas, Friis, & Herrstedt, 2012; Ording et al., 2013b; Ording et al., 2016) ; two studies found higher rates of cancerdementia patients in hospice nursing home residents (range 32%-43.2% in cancer-dementia and 16%-28.5% in non-cancer ) (Miller et al., 2001 (Miller et al., , 2002 : and one study found slightly lower rates of dementia in patients with cancer (1.3% in cancer-dementia and 1.9% in non-cancer) (Attner et al., 2010) .
Objective 2
Included studies for objective two are presented as cancer screening, cancer diagnosis, cancer treatment decisions and HCP views.
Cancer screening
Only three studies explored dementia and cancer screening (Smyth, 2009; Torke, Schwartz, Holtz, Montz, & Sachs, 2013; Walter et al., 2009 ). In a sample of male veterans with and without dementia, study findings show that only 19% of those with a diagnosis of dementia (2% of the sample) received colorectal cancer screening over 2 years compared to 47% with no morbidity or other morbidities such as diabetes (48%) or congestive heart failure (41%) (Walter et al., 2009) . Exploring possible reasons for reduced likelihood of receiving breast cancer screening, two studies (Smyth, 2009; Torke et al., 2013) explored the impact a diagnosis of dementia had on decisionmaking. Findings indicated that the involvement of the person with dementia in the decision-making process, potential distress from screening test procedures and the influence of the clinician are important decision-making factors.
Cancer diagnosis
Ten studies reported the impact of having a dementia diagnosis on the diagnostic processes of cancer (see Table 3 ). Five studies reported that some patients with dementia were diagnosed with cancer at autopsy three of which included control groups for comparison (Burke et al., 1994; Fu et al., 2004; Gupta & Lamont, 2004; Magaki, Yong, Khanlou, Tung, & Vinters, 2014) . Six studies reported that in the presence of dementia, it is less likely that a cancer diagnosis includes information on tumour size (cancer staging) (Baillargeon et al., 2011; Gupta & Lamont, 2004) and that cancer is diagnosed at a later stage of disease, compared to individuals without dementia (Odds Ratios; OR ranged from 0.97 to 2.31) (Bradley, Clement, & Lin, 2008; Gorin, Heck, Albert, & Hershman, 2005; Gupta & Lamont, 2004; Raji, Kuo, Freeman, & Goodwin, 2008; Tammemagi, Neslund-Dudas, Simoff, & Kvale, 2003) .
Cancer treatment decisions
Seven studies reported differences in cancer treatment decisions in samples of patients with cancer-dementia (see Table 3 ). Patients with a diagnosis of colon cancer and dementia were less likely to receive any treatment (OR 2.47), surgical (OR 0.43) or chemotherapy (OR range 0.21-3.23) treatment than those with cancer only (Baillargeon et al., 2011; Gupta & Lamont, 2004) . Another study with a colorectal sample found patients with dementia were less likely to receive chemotherapy (12.5%) compared to other comorbidities such as congestive heart failure (44.8%) . Similar findings were reported for breast cancer patients (Gorin et al., 2005; Kimmick et al., 2014) . However, a dementia diagnosis had no impact on whether patients received cancer-directed surgery in a sample of nursing home residents with breast, prostate, colorectal or lung cancer (Bradley et al., 2008) .
When considering the hypothetical scenario of a relative with dementia receiving a breast cancer diagnosis, carers with a relative with more severe dementia symptoms expressed 'comfort care' treatment as an option rather than treatment with curative intent (Smyth, 2009 Full-text arƟcles assessed for eligibility (n = 138)
Full-text arƟcles excluded, with reasons: n = 63 not co-morbid n=4 excluded history of demenƟa n = 14 couldn't exact sufficient data n=6 not confirmed demenƟa diagnosis n = 3 sample had cancer only at baseline
Studies included with quanƟtaƟve design (n =44)
Studies included with qualitaƟve design (n =3) previous 12 months 60% of clinicians recalled one or more nursing home residents with suspected breast cancer and a third (33%) chose not to refer for diagnostic testing or treatment (Hamaker et al., 2012) . Of the 121 responses relating to reasons why patients were not referred, a diagnosis of endstage dementia was the primary reason in over half of the cases (57%) and only 41% of decisions for non-referral were discussed with the patient. A small (n = 5) qualitative study identified: the need for experienced staff and specialist care for dementia patients dying with cancer; the provision of support to families; involving families in patient care decision-making; HCPs experience frustration due to the communication difficulties often associated with dementia and recommend that a holistic approach should be taken (Bartlett & Clarke, 2012) .
Objective 3
Studies relating to objective three are presented under the themes of management of cancer symptoms and cancer outcomes.
Management of cancer symptoms
Seven studies explored the management of cancer symptoms in patients with cancer-dementia (see final column, Table 3 ). Cross-sectional data indicated in two studies that as dementia severity increases, reported pain and administration of cancer pain medication decreases (Iritani, Tohgi, Miyata, & Ohi, 2011; Monroe, Carter, Feldt, Tolley, & Cowan, 2012) . Patients with cancer-dementia and higher scores on a cognitive ability scale used as a proxy for dementia severity (higher scores indicated greater impairment) were less likely to be enrolled in hospice care for cancer than patients with lower cognitive impairment (OR 0.3) and hospice enrolment was associated with greater likelihood of receiving pain medication (OR 3.9) (Monroe, Carter, Feldt, Dietrich, & Cowan, 2013) . In patients who died from a primary diagnosis of cancer and received hospice care in the six months prior to death, patients with cancer-dementia were more likely to use emergency health services, be admitted to hospital as an in-patient and no longer receive hospice services compared to patients with cancer alone (OR range 0.92-1.26) (Legler, Bradley, & Carlson, 2011) . Additionally, data from geriatric drug prescription databases in the USA showed that hospice enrolled nursing home residents with cancer-dementia were more likely to receive daily pain medication (OR 1.25) but were still more likely to be hospitalised than those with cancer only (OR 1.09) (Miller et al., 2001 (Miller et al., , 2002 . Lastly, comorbid metastatic cancer and dementia was associated with a longer stay in hospital and greater health care costs compared to in-patients with dementia only; the same findings were not reported in patients with nonmetastatic cancer or lymphoma (Beydoun et al., 2015) .
Cancer outcomes
Thirteen studies estimated the impact of a comorbid diagnosis of dementia on survival and/or mortality risk in cancer patients (Baillargeon et al., 2011; Beydoun et al., 2015; Bradley et al., 2008; Chen et al., 2015; Daskivich et al., 2011; Erichsen et al., 2013; Louwman et al., 2005; Mohammadi et al., 2015; O'Rourke et al., 2008; Ording et al., 2013b; Patnaik, Byers, DiGuiseppi, Denberg, & Dabelea, 2011; Raji et al., 2008; Tammemagi et al., 2003) . Periods of follow-up ranged from up to 5 years to 17 years from year of cancer diagnosis. All 13 studies reported an increased risk of death in patients with cancer-dementia compared to cancer only (all-cause hazard ratios range from 1.45 to 3.74; see Table 4 ). Five of these studies reported that those with cancer-dementia had a poorer survival rate than those with cancer and no comorbidity (Louwman et al., 2005; Mohammadi et al., 2015; Ording et al., 2013; Patnaik et al., 2011; Tammemagi et al., 2003) .
Discussion
This is a timely review given that the developed world comprises an ageing population with increased risk of developing both cancer and dementia. The primary aim of this review was to estimate cancer-dementia prevalence and describe the cancer-related journey of patients with cancer-dementia, their families and HCPs. In order to conduct a comprehensive review of the cancer-dementia literature, we used broad inclusion criteria and extracted data from a range of research methods that investigated a number of key themes including; cancer prevalence, cancer screening, diagnostic and treatment processes, cancer symptom management, and HCP views across these themes. We found no research that directly explored the views and experiences of patients. Furthermore, the review was limited by the sparse amount of studies evaluating the impact of cancer-dementia on cancer outcomes and low quality appraisal scores of included papers, with the majority of studies being retrospective and cross-sectional. Only one of the three qualitative studies met any criteria for appraisal using the MMAT tool, although only received one star of a possible four (Torke et al., 2013) .
In this review, prevalence rates for cancer-dementia varied widely. This is likely due to heterogeneity in data collection methods and sample inclusion criteria. The SEER register used in seven studies only covered about a quarter of the US population so is unlikely to reflect true prevalence (Taylor, Ostbye, Langa, Weir, & Plassman, 2009 ). Half of the included studies also used small regional databases or individual hospitals and 24 studies reported prevalence of specific cancer types. The highest prevalence rates were reported by Miller and colleagues and are difficult to generalise given that the two samples were nursing home residents at end of life using hospice care (Miller et al., 2001; Miller et al., 2002) . Additionally, the differences of reported dementia prevalence found between cancer and non-cancer control group studies are likely also to be indicative of varied data collection methods. However, in the studies that collected multiple comorbidity data, the prevalence of cancer-dementia was noticeably lower compared to other conditions such as diabetes, congestive heart failure and chronic obstructive pulmonary disease (Gross et al., 2006; Jorgensen et al., 2012) . No study provided sufficient data to comment on the presence of different types of dementia, the potential differences in cancer-related experiences and outcomes.
Little published evidence relates to the impact of dementia on cancer screening beliefs and behaviours. This, in part, is due to the exclusion of older adults aged 74 and older from screening trials, at least for breast cancer Walter & Schonberg, 2014) . The only study to investigate the impact of a dementia diagnosis on attending cancer screening found that patients were far less likely to attend colorectal screening if they had dementia, despite being a very small percentage of the total sample than for participants with no or any other comorbidity (Walter et al., 2009 ). The sample was aged 70 years or older so it may reflect the general decrease in guideline recommended screening behaviour, which typically ends at age 75 years old in the USA, regardless of comorbidity. The review findings suggest that compared with other comorbid disease groups, patients with dementia tend to be diagnosed with cancer at an unknown or later stage compared to patients with cancer only. This has likely implications for successful cancer treatment outcomes, potential to receive curative treatment and quality of life; as was found for comorbidities in general (Sarfati, Koczwara, & Jackson, 2016) . Other findings have demonstrated that older age can significantly impact cancer treatment decisions over and above comorbidity levels (Lavelle et al., 2012) . It may be that the patients with dementia included in this review had an advanced stage of disease or are older with associated health conditions such as frailty, which would impact on cancer treatment decisions. A recently developed framework for cancer-related end-of-life decision-making in the context of frailty could be adapted for use in patients with dementia (Ambl as-Novellas et al., 2015). Schonberg and colleagues did attempt to describe the factors influencing clinician treatment decisions in females aged 80 or older with breast cancer, however it was not possible to extract data on treatment decisions in relation to comorbid dementia (Schonberg, Silliman, McCarthy, & Marcantonio, 2012) . Although eligible studies should have been identified with the search terms used for this review, no included study explored palliative or end-of-life decision-making in patients with cancer-dementia and highlights an important and unmet research need in order to answer questions around treatment goals in this population. It could be that treatment goals are quality of life-based rather than for curative intent. This would suggest an even greater emphasis on the need for evidence-based guidelines to support cancer clinicians as well as patients with cancer-dementia and their caregivers.
While studies in the review reported varied prevalence rates for cancer-dementia, 11 out of 12 studies reported increased risk of death and poorer survival rates for this population compared to cancer only. Additionally, a comorbid diagnosis of dementia inferred a greater risk of death than other comorbidities such as congestive heart failure including cancer discovery after death. It is well known that multi-morbidity in older people negatively impacts on quality of life, but it is not yet clear why there appears to be a specific higher mortality risk in those with cancer-dementia (Marengoni et al., 2011) . One explanation could be the greater risk of death associated with frailty in older people; however, none of the included studies assessed the specific impact of this on cancer outcomes (Handforth, Young, Simpkins, Seymour, & Selby, 2015) .
The number and quality of papers reporting management of cancer symptoms in patients with cancer-dementia was low as demonstrated by the quality appraisal tool used to score each study. Our review demonstrates that dementiarelated impairments are likely to be related to suboptimal cancer-related pain assessment and management practices although further research is need to confirm these results (Monroe et al., 2012 (Monroe et al., , 2013 . It is well documented that people with dementia, without a cancer diagnosis, find it difficult to verbally communicate their experiences of pain and that tools used to assess pain need to be appropriate and sensitive to the needs of people with dementia Lichtner et al., 2016) . A single study reported increased use of emergency services and inpatient hospitalisation in patients with cancer-dementia; another reported greater healthcare costs for metastatic cancer although both were American studies with limited generalizability (Beydoun et al., 2015; Legler et al., 2011) . As yet, the economic impact of cancerdementia, although likely to be substantial in the absence of adequate clinical and support services, remains unknown. This review included limited research that explored HCPs' views and experiences in relation to cancer-dementia care at any stage of the cancer screening, diagnosis and treatment pathways. It is important to establish cancer treatment goals despite age or comorbidity as set out in recommendations for palliative support of patients with dementia (Naik, Martin, Moye, & Karel, 2016; van der Steen et al., 2013) . Given that we were unable to locate any high quality evidence of HCPs cancer treatment decision-making experiences for patients with cancer-dementia, future research should focus on exploring this given that we have reported lower likelihood of receiving cancer treatment and higher mortality risk in patients with comorbid dementia.
Clinical and policy implications
It is clear that the findings from this review indicate that a comorbid diagnosis of cancer and dementia has particular implications for healthcare service use, care management and delivery, which should be reflected in government policy and health guideline updates. At present, although quality standards published by the National Institute for Clinical Excellence (NICE, 2010, QS1) reflect that clinicians supporting patients with dementia should be adequately trained to provide dementia care, there is no mention of education regarding complex treatment decision-making discussions. However, there is a growing acknowledgement that there are specific priorities for the older population nationally and internationally that need to be addressed. For example, in the UK, implementation guidance on the second Prime Minister's challenge on dementia (Department of Health, 2016) advocates dementia-related research including comorbidity in older adults. Considerations also need to be made for the development of appropriate decision-making frameworks for this vulnerable population given the complexity clinicians, patients and their families' face, which has been alluded to in the findings from this review. Future work may involve conducting a systematic search of the grey literature to clarify this.
Conclusion
There is substantial variation in the reported cancer-dementia prevalence rate yet cancer-dementia appears to present as a unique challenge for the patient, carer and clinicians. Additional work is required to investigate the impact of different levels of dementia severity on the cancer pathway from prevention, diagnosis to end of life. Further investigations are warranted to understand and optimise the cancer care pathways for these at-risk individuals.
